- Home
- TPG vs MDGL Comparison
TPG vs MDGL Comparison
Compare TPG & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPG
- MDGL
- Stock Information
- Founded
- TPG 1992
- MDGL 2011
- Country
- TPG United States
- MDGL United States
- Employees
- TPG N/A
- MDGL N/A
- Industry
- TPG Investment Managers
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- TPG Finance
- MDGL Health Care
- Exchange
- TPG Nasdaq
- MDGL Nasdaq
- Market Cap
- TPG 7.0B
- MDGL 6.4B
- IPO Year
- TPG 2022
- MDGL N/A
- Fundamental
- Price
- TPG $67.03
- MDGL $293.64
- Analyst Decision
- TPG Buy
- MDGL Buy
- Analyst Count
- TPG 13
- MDGL 14
- Target Price
- TPG $60.75
- MDGL $351.67
- AVG Volume (30 Days)
- TPG 952.8K
- MDGL 413.3K
- Earning Date
- TPG 02-11-2025
- MDGL 02-26-2025
- Dividend Yield
- TPG 2.27%
- MDGL N/A
- EPS Growth
- TPG N/A
- MDGL N/A
- EPS
- TPG N/A
- MDGL N/A
- Revenue
- TPG $3,406,805,000.00
- MDGL $76,813,000.00
- Revenue This Year
- TPG N/A
- MDGL N/A
- Revenue Next Year
- TPG $16.57
- MDGL $194.49
- P/E Ratio
- TPG $2,777.14
- MDGL N/A
- Revenue Growth
- TPG 84.54
- MDGL N/A
- 52 Week Low
- TPG $39.16
- MDGL $168.25
- 52 Week High
- TPG $72.98
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- TPG 55.66
- MDGL 45.07
- Support Level
- TPG $61.13
- MDGL $266.44
- Resistance Level
- TPG $66.61
- MDGL $343.97
- Average True Range (ATR)
- TPG 1.74
- MDGL 17.83
- MACD
- TPG 0.34
- MDGL -4.57
- Stochastic Oscillator
- TPG 97.52
- MDGL 35.08
About TPG TPG Inc.
TPG Inc is an alternative asset firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, and Market Solutions. TPG aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment and performance of its portfolio.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.